Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Amendment Acknowledgment Letter - RECOTHROM

Our STN: BL 125248/0

ZymoGenetics, Inc.
Attention: Mr. Mark W. Gauthier
1201 Eastlake Avenue East
Seattle, WA 98102

Dear Mr. Gauthier:

We received your July 31, 2007 amendment to your biologics license application (BLA) submitted under section 351 of the Public Health Service Act for Thrombin (Recombinant) on August 1, 2007.

We consider your submission a major amendment under the Prescription Drug User Fee Act of 1992.

Because we received this major amendment within three months of the action due date on this application we will add an additional three months to the time by which we should complete our review. Therefore, the goal date is January 17, 2008.

If you have any questions, please contact the Regulatory Project Manager, Mark Shields, at (301) 827-6173.

Sincerely yours,

/Basil Golding, M.D./
Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 02/12/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.